Tyra Biosciences Prices $400M Underwritten Offering at $22.03/Share
TYRA has more than doubled off its 52-week low of $11.82 on elevated volume (2.4× avg).
Summary
Tyra Biosciences priced a $400M underwritten offering of 9.08M shares and 9.08M pre-funded warrants at $22.03, led by RA Capital with participation from top-tier biotech funds. Proceeds fund the dabogratinib 3x3 development strategy following positive Phase 2 bladder cancer data.
Key Events · Financing and Capital Events · TYRA
-
$400M Underwritten Offering Priced
9,079,000 common shares at $22.03 and 9,078,529 pre-funded warrants at $22.029, for gross proceeds of approximately $400 million before fees.
-
Pre-Funded Warrants Economically Equivalent to Common
Warrants carry a $0.001 exercise price, are immediately exercisable, and never expire — effectively common stock with a nominal strike. Beneficial ownership blockers set at 4.99%, 9.99%, or 19.99% per holder.
-
Underwriter Compensation and Lock-Up
Underwriters purchased at $20.7082 per share ($1.3218 discount, ~6%). Directors and executive officers subject to 60-day lock-up; ATM sales paused for 30 days.
-
Use of Proceeds: Dabogratinib 3x3 Strategy
Net proceeds fund development of dabogratinib in LG-UTUC, IR NMIBC, and achondroplasia, plus preclinical programs and working capital. Company held $353.9M cash as of Q2 2026.
Analysis · TYRA · Life Sciences
Just days after reporting positive Phase 2 SURF302 data for dabogratinib in bladder cancer, Tyra Biosciences locked in a $400 million capital raise. The offering — 9.08M common shares plus 9.08M pre-funded warrants at $22.03 — was led by RA Capital Management with participation from blue-chip biotech investors including BVF Partners, Commodore Capital, and Janus Henderson. Priced at a modest discount to the $25.20 current price, the deal reflects strong institutional demand rather than distress. Proceeds fund the dabogratinib 3x3 development strategy across LG-UTUC, IR NMIBC, and achondroplasia, extending an already-strong cash position of $353.9M as of Q2 2026. The pre-funded warrants carry a nominal $0.001 exercise price and no expiration, meaning they are economically equivalent to common shares and will convert to common stock almost immediately. Underwriters received a 6% discount ($1.3218 per share), and the company agreed to a 60-day lock-up on insider sales plus a 30-day pause on ATM sales. This is a well-subscribed, premium-priced raise that validates the clinical data and removes any near-term financing overhang.
How filings like this one have moved
In the 30 days to Nov 8, 2026, 46.9% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TYRA was trading at $25.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.82 to $40.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.